Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2013

01-08-2013 | Review Article

Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations

Authors: Alisa N. Femia, Ruth Ann Vleugels, Jeffrey P. Callen

Published in: American Journal of Clinical Dermatology | Issue 4/2013

Login to get access

Abstract

Dermatomyositis is a specific type of inflammatory myopathy with characteristic cutaneous findings. Patients may have skin disease without clinically apparent muscle disease, but this disorder is best thought of as a systemic process. Therefore, all patients with dermatomyositis skin lesions need appropriate evaluation for muscle disease, esophageal dysfunction, cardiopulmonary disease, and potential internal malignancy. There are many therapies that have been used for patients with dermatomyositis, but most are based upon case series or expert opinion rather than meta-analyses or randomized, placebo-controlled trials. Even those therapies that have been subjected to randomized, blinded, placebo-controlled trials include a mixture of patients with idiopathic inflammatory myopathy and do not utilize a validated assessment tool for measuring cutaneous disease responses. In this review, we discuss the therapies available as well as the internal associations with dermatomyositis.
Literature
1.
2.
Dalakas MC. Review: an update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol. 2011;37(3):226–42.CrossRefPubMed
3.
Nagaraju K, Lundberg IE. Polymyositis and dermatomyositis: pathophysiology. Rheum Dis Clin N Am. 2011;37(2):159–71 v.CrossRef
4.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.CrossRefPubMed
5.
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.CrossRefPubMed
6.
Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.CrossRefPubMed
7.
Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26–30.CrossRefPubMed
8.
Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother. 2004;5(5):1083–99.CrossRefPubMed
9.
Klein RQ, Teal V, Taylor L, Troxel AB, Werth VP. Number, characteristics, and classification of patients with dermatomyositis seen by dermatology and rheumatology departments at a large tertiary medical center. J Am Acad Dermatol. 2007;57(6):937–43.CrossRefPubMed
10.
Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol. 2010;32(3):189–91.CrossRefPubMed
11.
Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92(1):25–41.CrossRef
12.
Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22(7):1300–3.PubMed
13.
Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326(6):363–7.CrossRefPubMed
14.
Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357(9250):96–100.CrossRefPubMed
15.
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087–95.CrossRefPubMed
16.
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85(1):41–5.CrossRefPubMed
17.
Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6(1):9–13.CrossRefPubMed
18.
Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ, et al. Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol. 2009;161(4):854–60.CrossRefPubMed
19.
Kuo CF, See LC, Yu KH, Chou IJ, Chang HC, Chiou MJ, et al. Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: a nationwide population study. Br J Dermatol. 2011;165(6):1273–9.CrossRefPubMed
20.
Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF. Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol. 2009;36(12):2704–10.CrossRefPubMed
21.
Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011;65(6):1107–16.CrossRefPubMed
22.
Callen JP. Photosensitivity in collagen vascular diseases. Semin Cutan Med Surg. 1999;18(4):293–6.CrossRefPubMed
23.
Sontheimer RD. Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review. Photochem Photobiol. 1996;63(5):583–94.CrossRefPubMed
24.
Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW, International Myositis Collaborative Study G. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003;48(8):2285–93.CrossRefPubMed
25.
Love LA, Weinberg CR, McConnaughey DR, Oddis CV, Medsger TA Jr, Reveille JD, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60(8):2499–504.CrossRefPubMed
26.
Dourmishev L, Meffert H, Piazena H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed. 2004;20(5):230–4.CrossRefPubMed
27.
Cheong WK, Hughes GR, Norris PG, Hawk JL. Cutaneous photosensitivity in dermatomyositis. Br J Dermatol. 1994;131(2):205–8.CrossRefPubMed
28.
Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):824–9.PubMed
29.
Quain RD, Werth VP. Management of cutaneous dermatomyositis: current therapeutic options. Am J Clin Dermatol. 2006;7(6):341–51.CrossRefPubMed
30.
Ring J, Mohrenschlager M, Henkel V. The US FDA ‘black box’ warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf. 2008;31(3):185–98.CrossRefPubMed
31.
Kim JE, Jeong MG, Lee HE, Ko JY, Ro YS. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol. 2011;23(3):348–51.CrossRefPubMed
32.
Lampropoulos CE, D’Cruz DP. Topical tacrolimus treatment in a patient with dermatomyositis. Ann Rheum Dis. 2005;64(9):1376–7.CrossRefPubMed
33.
Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12(1):50–2.PubMed
34.
Ueda M, Makinodan R, Matsumura M, Ichihashi M. Successful treatment of amyopathic dermatomyositis with topical tacrolimus. Br J Dermatol. 2003;148(3):595–6.CrossRefPubMed
35.
Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: a pilot study. J Dermatolog Treat. 2004;15(1):35–9.CrossRefPubMed
36.
Peyrot I, Sparsa A, Loustaud-Ratti V, Liozon E, Vidal E, Bonnetblanc JM, et al. Topical tacrolimus and resistant skin lesions of dermatomyositis. Rev Med Interne. 2006;27(10):730–5.
37.
Soter NA, Fleischer AB Jr, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001;44(1 Suppl):S39–46.CrossRefPubMed
38.
Garcia-Doval I, Cruces M. Topical tacrolimus in cutaneous lesions of dermatomyositis: lack of effect in side-by-side comparison in five patients. Dermatology. 2004;209(3):247–8.CrossRefPubMed
39.
Shirani Z, Kucenic MJ, Carroll CL, Fleischer AB Jr, Feldman SR, Yosipovitch G, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004;29(3):273–6.CrossRefPubMed
40.
Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol. 2010;9(8):992–7.PubMed
41.
Taylor JE, Richelson E. High affinity binding of tricyclic antidepressants to histamine H1-receptors: fact and artifact. Eur J Pharmacol. 1980;67(1):41–6.CrossRefPubMed
42.
Yuen WY, Schuttelaar ML, Barkema LW, Coenraads PJ. Bullous allergic contact dermatitis to lidocaine. Contact Dermat. 2009;61(5):300–1.CrossRef
43.
Coskey RJ. Adverse effects of corticosteroids: I. Topical and intralesional. Clin Dermatol. 1986;4(1):155–60.CrossRefPubMed
44.
Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges. 2010;8(10):829–44; Quiz 845.
45.
Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a reexamination. Semin Arthritis Rheum. 1989;18(4):282–96.CrossRefPubMed
46.
Cox NH. Amyopathic dermatomyositis, photosensitivity and hydroxychloroquine. Br J Dermatol. 1995;132(6):1016–7.PubMed
47.
Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10(4):592–600.CrossRefPubMed
48.
Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinal SH, Hinds A. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol. 1998;38(3):397–404.CrossRefPubMed
49.
Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141(7):855–9.CrossRefPubMed
50.
Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16(12):1545–7.PubMed
51.
Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231–3 discussion 3.CrossRefPubMed
52.
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415–22.CrossRefPubMed
53.
Callen JP, Camisa C. Antimalarial agents. In: Wolverton SE, editor. Comprehensive dermatologic drug therapy. Philadelphia: Saunders Elsevier; 2007.
54.
Casado E, Gratacos J, Tolosa C, Martinez JM, Ojanguren I, Ariza A, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65(3):385–90.CrossRefPubMed
55.
Foulke G, Baccon J, Marks JG, Clarke JT. Antimalarial myopathy in amyopathic dermatomyositis. Arch Dermatol. 2012;148(9):1100–1.CrossRefPubMed
56.
Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol. 1998;25(9):1716–9.PubMed
57.
Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145(3):244–8.CrossRefPubMed
58.
Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000;42(6):983–7.CrossRefPubMed
59.
Lardet D, Martin S, Truchetet F, Cuny JF, Virion JM, Schmutz JL. Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study. Rev Med Interne. 2004;25(11):786–91.
60.
Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, et al. Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol. 2011;131(10):1981–6.CrossRefPubMed
61.
Giannini M, Callen JP. Treatment of dermatomyositis with methotrexate and prednisone. Arch Dermatol. 1979;115(10):1251–2.CrossRefPubMed
62.
Reich K, Domm S, Mrowietz U. Methotrexate therapy in dermatology. J Dtsch Dermatol Ges. 2012;10(5):363–70.PubMed
63.
Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994;370:411–6.PubMed
64.
65.
Ramirez G, Asherson RA, Khamashta MA, Cervera R, D’Cruz D, Hughes GR. Adult-onset polymyositis-dermatomyositis: description of 25 patients with emphasis on treatment. Semin Arthritis Rheum. 1990;20(2):114–20.CrossRefPubMed
66.
Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24(5):457–62.CrossRefPubMed
67.
Malaviya AN, Many A, Schwartz RS. Treatment of dermatomyositis with methotrexate. Lancet. 1968;2(7566):485–8.CrossRefPubMed
68.
Hornung T, Ko A, Tuting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139–42.CrossRefPubMed
69.
Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5 Pt 1):754–7.CrossRefPubMed
70.
Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67–71.CrossRefPubMed
71.
Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974;81(2):182–9.CrossRefPubMed
72.
Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28(10):2230–7.PubMed
73.
Zieglschmid-Adams ME, Pandya A, Cohen SB, Sontheimer RD. The value of methotrexate in dermatomyositis. J Am Acad Dermatol. 1998;38(1):130–2.PubMed
74.
Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum. 1992;35(10):1143–9.CrossRefPubMed
75.
Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–8.CrossRefPubMed
76.
Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138–41.CrossRefPubMed
77.
Fischer TJ, Rachelefsky GS, Klein RB, Paulus HE, Stiehm ER. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone. Am J Dis Child. 1979;133(4):386–9.PubMed
78.
Barker J, Horn EJ, Lebwohl M, Warren RB, Nast A, Rosenberg W, et al. Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. J Eur Acad Dermatol Venereol. 2011;25(7):758–64.CrossRefPubMed
79.
Kalantzis A, Marshman Z, Falconer DT, Morgan PR, Odell EW. Oral effects of low-dose methotrexate treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(1):52–62.CrossRefPubMed
80.
Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003;139(11):1425–9.CrossRefPubMed
81.
Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol. 2006;142(9):1132–5.CrossRefPubMed
82.
Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19(1 Pt 1):145–56.CrossRefPubMed
83.
Orvis AK, Wesson SK, Breza TS Jr, Church AA, Mitchell CL, Watkins SW. Mycophenolate mofetil in dermatology. J Am Acad Dermatol. 2009;60(2):183–99 quiz 200–2.CrossRefPubMed
84.
Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66(8):1245–7.CrossRefPubMed
85.
Majithia V, Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44(3):386–9.CrossRef
86.
Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27(6):1542–5.PubMed
87.
88.
Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142(1):65–9.CrossRefPubMed
89.
Dagher R, Desjonqueres M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711–6.CrossRefPubMed
90.
Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446–51.CrossRef
91.
Vernino S, Salomao DR, Habermann TM, O’Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005;65(4):639–41.CrossRefPubMed
92.
Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–89.CrossRefPubMed
93.
Hollingworth P, de Vere Tyndall A, Ansell BM, Platts-Mills T, Gumpel JM, Mertin J, et al. Intensive immunosuppression versus prednisolone in the treatment of connective tissue diseases. Ann Rheum Dis. 1982;41(6):557–62.CrossRefPubMed
94.
Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379–87.CrossRefPubMed
95.
Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41(3):392–9.CrossRefPubMed
96.
Miller J, Walsh Y, Saminaden S, Lecky BR, Winer JB. Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci. 2002;199:S53.
97.
Ng YT, Ouvrier RA, Wu T. Drug therapy in juvenile dermatomyositis: follow-up study. J Child Neurol. 1998;13(3):109–12.CrossRefPubMed
98.
Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr. 1987;26(11):561–6.CrossRef
99.
Jacobs JC. Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics. 1977;59(2):212–8.PubMed
100.
Ponyi A, Constantin T, Balogh Z, Szalai Z, Borgulya G, Molnar K, et al. Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis. Clin Exp Rheumatol. 2005;23(1):50–6.PubMed
101.
Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol. 1998;134(1):80–6.CrossRefPubMed
102.
Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Investig. 1994;94(5):1729–35.CrossRefPubMed
103.
Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med. 1991;91(2):162–8.CrossRefPubMed
104.
Esteve E, Cambie MP, Serpier H, Vanderbroere-Bouquet A, Bellaiche P, Kalis B. Paraneoplastic dermatomyositis: efficacy of intravenous gammaglobulin. Br J Dermatol. 1994;131(6):917–8.CrossRefPubMed
105.
Kikuchi-Numagami K, Sato M, Tagami H. Successful treatment of a therapy-resistant severely pruritic skin eruption of malignancy-associated dermatomyositis with high-dose intravenous immunoglobulin. J Dermatol. 1996;23(5):340–3.PubMed
106.
Moriguchi M, Suzuki T, Tateishi M, Hara M, Kashiwazaki S. Intravenous immunoglobulin therapy for refractory myositis. Intern Med. 1996;35(8):663–7.CrossRefPubMed
107.
Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. Eur J Dermatol. 2000;10(1):29–35.PubMed
108.
Kuwano Y, Ihn H, Yazawa N, Kakinuma T, Asahina A, Kikuchi K, et al. Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin. Acta Derm Venereol. 2006;86(2):158–9.PubMed
109.
Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993–2000.CrossRefPubMed
110.
Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18(1):34–44.CrossRefPubMed
111.
Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev. 2009;9(2):124–7.CrossRefPubMed
112.
Penate Y, Guillermo N, Melwani P, Martel R, Hernandez-Machin B, Borrego L. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol. 2009;60(6):1076–7.CrossRefPubMed
113.
Sabroe RA, Wallington TB, Kennedy CT. Dermatomyositis treated with high-dose intravenous immunoglobulins and associated with panniculitis. Clin Exp Dermatol. 1995;20(2):164–7.CrossRefPubMed
114.
Sadayama T, Miyagawa S, Shirai T. Low-dose intravenous immunoglobulin therapy for intractable dermatomyositis skin lesions. J Dermatol. 1999;26(7):457–9.PubMed
115.
Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Ziza JM, et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet. 1990;336(8707):116.CrossRefPubMed
116.
Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61(1):37–41.CrossRefPubMed
117.
Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufas AG. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol. 2012;30(3):397–401.PubMed
118.
Peake MF, Perkins P, Elston DM, Older SA, Vinson RP. Cutaneous ulcers of refractory adult dermatomyositis responsive to intravenous immunoglobulin. Cutis. 1998;62(2):89–93.PubMed
119.
Bodemer C, Teillac D, Le Bourgeois M, Wechsler B, de Prost Y. Efficacy of intravenous immunoglobulins in sclerodermatomyositis. Br J Dermatol. 1990;123(4):545–6.CrossRefPubMed
120.
Mosca M, Strigini F, Carmignani A, D’Ascanio A, Genazzani AR, Bombardieri S. Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum. 2005;53(1):119–21.CrossRefPubMed
121.
Williams L, Chang PY, Park E, Gorson KC, Bayer-Zwirello L. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy. Obstet Gynecol. 2007;109(2 Pt2):561–3.CrossRefPubMed
122.
Linardaki G, Cherouvim E, Goni G, Boki KA. Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis. Rheumatol Int. 2011;31(1):113–5.CrossRefPubMed
123.
Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201–6.CrossRefPubMed
124.
Touimy M, Janani S, Rachidi W, Etaouil N, Mkinsi O. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine. 2013;80(1):108–9.
125.
Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D. Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol. 1994;130(2):231–4.CrossRefPubMed
126.
Kokori H, Fotoulaki M, Giannakopoulou C, Hatzidaki E, Tantros S, Sbyrakis S. Intravenous immunoglobulin treatment in a girl with juvenile dermatomyositis. Pediatr Int. 1999;41(6):696–7.PubMed
127.
Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70(12):2089–94.CrossRefPubMed
128.
Feldmeyer L, Benden C, Haile SR, Boehler A, Speich R, French LE, et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol. 2010;90(5):494–7.CrossRefPubMed
129.
Epstein JS GA, Kapit R, et al. Important drug warning immune globulin intravenous. FDA Medical Bulletin. 2003.
130.
Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44(2):223–6.CrossRefPubMed
131.
Steinberger B, Coleman TA. Multiple complications of IVIG therapy in a patient with Guillain-Barre syndrome. Am J Hematol. 2001;67(1):59.CrossRefPubMed
132.
133.
van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20(6):382–9.CrossRefPubMed
134.
Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6(3):129–37.CrossRefPubMed
135.
136.
Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420–34.CrossRefPubMed
137.
Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129(5):507–13.CrossRefPubMed
138.
Cohen JB. Cutaneous involvement of dermatomyositis can respond to dapsone therapy. Int J Dermatol. 2002;41(3):182–4.CrossRefPubMed
139.
Konohana A, Kawashima J. Successful treatment of dermatomyositis with dapsone. Clin Exp Dermatol. 1994;19(4):367.CrossRefPubMed
140.
Galrao LDA, RJ, Lima I, Santiago M. Efficacy of dapsone in two cases of amyopathic dermatomyositis. An Bras Dermatol. 2006;41:182–4.
141.
Kawachi Y, Fujisawa Y, Furuta J, Nakamura Y, Ishii Y, Otsuka F. Pruritic poikilodermatous eruption associated with dermatomyositis: successful treatment with dapsone. Eur J Dermatol. 2012;22(2):289–90.PubMed
142.
Zhang Q, Cui F, Fang L, Hong J, Zheng B, Zhang JZ. TNF-α impairs differentiation and function of TGF-β-induced Treg cells in autoimmune diseases through AKt and Smad3 signaling pathway. J Mol Cell Biol. 2013;5(2):85–98.
143.
Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995;63(1):9–16.CrossRefPubMed
144.
Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G. Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol. 2000;99(5):585–8.CrossRefPubMed
145.
146.
Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427–36.
147.
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33(9):1802–4.PubMed
148.
Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65(9):1233–6.CrossRefPubMed
149.
Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54(3 Suppl 2):S139–42.CrossRefPubMed
150.
Korkmaz C, Temiz G, Cetinbas F, Buyukkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford). 2004;43(7):937–8.CrossRef
151.
Selva-O’Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford). 2004;43(9):1196–7.CrossRef
152.
Roddy E, Courtney PA, Morris A. Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford). 2002;41(10):1194–5.CrossRef
153.
Dold S, Justiniano ME, Marquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26(7):1186–8.CrossRefPubMed
154.
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67(12):1670–7.CrossRefPubMed
155.
Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59(3–4):159–63.CrossRefPubMed
156.
Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877–80.CrossRef
157.
Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146(7):780–4.CrossRefPubMed
158.
Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol. 2010;37(7):1549–50.CrossRefPubMed
159.
Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum. 2006;55(6):982–4.CrossRefPubMed
160.
Emer JJ, Claire W. Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol. 2009;2(5):29–37.
161.
162.
Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763–7.CrossRefPubMed
163.
Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601–7.CrossRefPubMed
164.
Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33(5):1021–6.PubMed
165.
Chiappetta N, Steier J, Gruber B. Rituximab in the treatment of refractory dermatomyositis. J Clin Rheumatol. 2005;11(5):264–6.CrossRefPubMed
166.
Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol. 2005;32(7):1369–70.PubMed
167.
Dinh HV, McCormack C, Hall S, Prince HM. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. J Am Acad Dermatol. 2007;56(1):148–53.CrossRefPubMed
168.
Touma Z, Arayssi T, Kibbi L, Masri AF. Successful treatment of cardiac involvement in dermatomyositis with rituximab. Jt Bone Spine. 2008;75(3):334–7.CrossRef
169.
Feist E, Dorner T, Sorensen H, Burmester GR. Longlasting remissions after treatment with rituximab for autoimmune myositis. J Rheumatol. 2008;35(6):1230–2.PubMed
170.
Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology. 2011;50(12):2206–13.CrossRefPubMed
171.
Sultan SM, Ng KP, Edwards JC, Isenberg DA, Cambridge G. Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy. Clin Exp Rheumatol. 2008;26(5):887–93.PubMed
172.
Kaposztas Z, Etheridge WB, Kahan BD. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus. Transpl Proc. 2008;40(5):1744–6.CrossRef
173.
Haroon M, Devlin J. Rituximab as a first-line agent for the treatment of dermatomyositis. Rheumatol Int. 2012;32(6):1783–4.CrossRefPubMed
174.
Parziale N, Kovacs SC, Thomas CB, Srinivasan J. Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders. J Clin Neuromuscular Dis. 2011;13(2):63–7.CrossRef
175.
Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, Saez Moreno JA, Ortego Centeno N. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature. Clin Exp Rheumatol. 2009;27(6):1009–16.PubMed
176.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.
177.
de Visser M. The efficacy of rituximab in refractory myositis: the jury is still out. Arthritis Rheum. 2013;65(2):303–6.
178.
Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum. 2007;56(9):3107–11.CrossRefPubMed
179.
Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.CrossRefPubMed
180.
Medication guide: Rituxan® (ri-tuk-san) (rituximab) for injection. In: Genetech IaBI, Inc, editor; 2012.
181.
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834–40.CrossRefPubMed
182.
Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol. 2010;63(6):925–46 quiz 47–8.CrossRefPubMed
183.
Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry. 1991;54(11):1007–8.CrossRefPubMed
184.
Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95–102.CrossRefPubMed
185.
186.
Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27(12):2855–9.PubMed
187.
Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol. 1997;26(1):24–9.CrossRefPubMed
188.
Kavanagh GM, Ross JS, Black MM. Dermatomyositis treated with cyclosporin. J R Soc Med. 1991;84(5):306.PubMed
189.
Danko K, Szegedi G. Cyclosporin A treatment of dermatomyositis. Arthritis Rheum. 1991;34(7):933–4.CrossRefPubMed
190.
Grau JM, Herrero C, Casademont J, Fernandez-Sola J, Urbano-Marquez A. Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol. 1994;21(2):381–2.PubMed
191.
Saadeh C, Bridges W, Burwick F. Dermatomyositis: remission induced with combined oral cyclosporine and high-dose intravenous immune globulin. South Med J. 1995;88(8):866–70.CrossRefPubMed
192.
Shimojima Y, Ishii W, Kato T, Hoshi K, Matsuda M, Hashimoto T, et al. Intractable skin necrosis and interstitial pneumonia in amyopathic dermatomyositis, successfully treated with cyclosporin A. Intern Med. 2003;42(12):1253–8.CrossRefPubMed
193.
Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35(2):254–9.PubMed
194.
Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30(8):1021–8.CrossRefPubMed
195.
Kim HJ, Hong YK, Yoo WH. Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature. Rheumatol Int. 2009;29(9):1101–4.CrossRefPubMed
196.
Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24(12):2436–43.PubMed
197.
Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, et al. Cyclosporin in juvenile dermatomyositis. Lancet. 1989;1(8646):1063–6.CrossRefPubMed
198.
Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol. 1996;23(8):1424–7.PubMed
199.
Hamill G, Saunders C, Heckmatt J, Dubowitz V, Stanhope R. “Catch-up” growth in steroid dependent dermatomyositis treated with cyclosporin-A. Eur J Med. 1992;1(1):16–8.PubMed
200.
Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44(11):1197–9.CrossRefPubMed
201.
Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr. 2004;163(9):561–2.CrossRefPubMed
202.
Modesto C, Boronat M, Marsal S, Arnal-Guimera C. FK-506 in the treatment of unresponsive juvenile dermatomyositis. Ann Rheum Dis. 2000;59:728.
203.
Martin Nalda A, Modesto Caballero C, Arnal Guimeral C, Boronat Rom M, Barcelo Garcia P. Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc). 2006;127(18):697–701.CrossRef
204.
Hassan J, van der Net JJ, van Royen-Kerkhof A. Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol. 2008;27(11):1469–71.CrossRefPubMed
205.
Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol. 2007;57(6):1046–50.CrossRefPubMed
206.
Nadiminti U, Arbiser JL. Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol. 2005;52(2 Suppl 1):17–9.CrossRefPubMed
207.
Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, Vilardell-Tarres M, Ordi-Ros J. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166(3):616–23.CrossRefPubMed
208.
Flores-Suarez LF, Morales H, Angeles A, Kraus A. Drug-induced amyopathic dermatomyositis. J Clin Rheumatol. 2002;8(1):50–4.CrossRefPubMed
209.
Miyamae T, Sano F, Ozawa R, Imagawa T, Inayama Y, Yokota S. Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J. 2010;8(1):6.CrossRefPubMed
210.
Sugisaki K, Takeda I, Iwadate H, Kanno T, Nishimaki T, Kasukawa R. Prevention of progression of interstitial lung lesions by early combination therapy with corticosteroids and cyclosporine/cyclophosphamide in two patients with amyopathic dermatomyositis. Fukushima J Med Sci. 2002;48(2):103–10.PubMed
211.
Tanaka F, Origuchi T, Migita K, Tominaga M, Kawakami A, Kawabe Y, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. Intern Med. 2000;39(5):428–30.CrossRefPubMed
212.
al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol. 1989;16(12):1592–6.PubMed
213.
Meyer O, Hayem G, Palazzo E, Crestani B, Debray MP, Ballard M. Interstitial lung disease due to polymyositis or dermatomyositis: effect of a 6-month course of i.v. pulse cyclophosphamide. Clin Exp Rheumatol. 2005;23(5):724.PubMed
214.
Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124–30.CrossRef
215.
Tsujimura S, Saito K, Tanaka Y. Complete resolution of dermatomyositis with refractory cutaneous vasculitis by intravenous cyclophosphamide pulse therapy. Intern Med. 2008;47(21):1935–40.CrossRefPubMed
216.
Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491–6.CrossRef
217.
Nakashima S, Mori M, Miyamae T, Ito S, Ibe M, Aihara Y, et al. Intravenous cyclophosphamide pulse therapy for refractory juvenile dermatomyositis. Ryumachi [Rheumatism]. 2002;42(6):895–902.
218.
Sangle VS, Sangle SR, D’Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis. 2008;67(5):723.CrossRefPubMed
219.
Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58(3):403–6.CrossRefPubMed
220.
Sereda D, Werth VP. Improvement in dermatomyositis rash associated with the use of antiestrogen medication. Arch Dermatol. 2006;142(1):70–2.CrossRefPubMed
221.
Kelly JJ, Madoc-Jones H, Adelman LS, Andres PL, Munsat TL. Response to total body irradiation in dermatomyositis. Muscle Nerve. 1988;11(2):120–3.CrossRefPubMed
222.
Chakraverty R, Rabin N, Peggs K, Robinson S, Duncan JR, Yong K. Dermatomyositis and sarcoid-like reaction associated with multiple myeloma treated effectively by high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;27(11):1215–7.CrossRefPubMed
223.
Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70(7):1285–8.CrossRefPubMed
224.
Holzer U, van Royen-Kerkhof A, van der Torre P, Kuemmerle-Deschner J, Well C, Handgretinger R, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol. 2010;39(1):88–92.CrossRefPubMed
225.
Pons-Estel GJ, Salerni GE, Serrano RM, Gomez-Puerta JA, Plasin MA, Aldasoro E, et al. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev. 2011;10(11):679–84.CrossRefPubMed
226.
Cherin P, Auperin I, Bussel A, Pourrat J, Herson S. Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases. Clin Exp Rheumatol. 1995;13(2):270–1.PubMed
227.
Brewer EJ Jr, Giannini EH, Rossen RD, Patten B, Barkley E. Plasma exchange therapy of a childhood onset dermatomyositis patient. Arthritis Rheum. 1980;23(4):509–13.CrossRefPubMed
228.
Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol. 1981;38(9):544–52.CrossRefPubMed
229.
Clarke CR, Dyall-Smith DJ, Mackay IR, Emery P, Jennens ID, Becker G. Plasma exchange in dermatomyositis/polymyositis: beneficial effects in three cases. J Clin Lab Immunol. 1988;27(3):149–52.PubMed
230.
Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326(21):1380–4.CrossRefPubMed
231.
Callen JP, Hyla JF, Bole GG Jr, Kay DR. The relationship of dermatomyositis and polymyositis to internal malignancy. Arch Dermatol. 1980;116(3):295–8.CrossRefPubMed
232.
Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P, et al. The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int. 2013;33(4):965–71.
233.
So MW, Koo BS, Kim YG, Lee CK, Yoo B. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol. 2011;38(11):2432–5.CrossRefPubMed
234.
Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21(10):1855–9.PubMed
235.
Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597–613.CrossRefPubMed
236.
Mebazaa A, Boussen H, Nouira R, Rokbani L, Ben Osman-Dhahri A, Bouaouina N, et al. Dermatomyositis and malignancy in Tunisia: a multicenter national retrospective study of 20 cases. J Am Acad Dermatol. 2003;48(4):530–4.CrossRefPubMed
237.
Liu WC, Ho M, Koh WP, Tan AW, Ng PP, Chua SH, et al. An 11-year review of dermatomyositis in Asian patients. Ann Acad Med Singap. 2010;39(11):843–7.PubMed
238.
Chen DY, Chen YM, Lan JL, Chen HH, Hsieh CW, Wey SJ, et al. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein–Barr virus connection? J Clin Virol. 2010;49(4):290–5.CrossRefPubMed
239.
Callen JP. The value of malignancy evaluation in patients with dermatomyositis. J Am Acad Dermatol. 1982;6(2):253–9.CrossRefPubMed
240.
Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica. 1990;180(4):212–6.CrossRefPubMed
241.
Moss AA, Hanelin LG. Occult malignant tumors in dermatologic disease. The futility of radiological search. Radiology. 1977;123(1):69–71.PubMed
242.
Schulman P, Kerr LD, Spiera H. A reexamination of the relationship between myositis and malignancy. J Rheumatol. 1991;18(11):1689–92.PubMed
243.
Sparsa A, Liozon E, Herrmann F, Ly K, Lebrun V, Soria P, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis: a study of 40 patients. Arch Dermatol. 2002;138(7):885–90.CrossRefPubMed
244.
Davis MD, Ahmed I. Ovarian malignancy in patients with dermatomyositis and polymyositis: a retrospective analysis of fourteen cases. J Am Acad Dermatol. 1997;37(5 Pt 1):730–3.CrossRefPubMed
245.
Selva-O’Callaghan A, Grau JM, Gamez-Cenzano C, Vidaller-Palacin A, Martinez-Gomez X, Trallero-Araguas E, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med. 2010;123(6):558–62.CrossRefPubMed
246.
Fardet L, Dupuy A, Gain M, Kettaneh A, Cherin P, Bachelez H, et al. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore). 2009;88(2):91–7.CrossRef
247.
Zhang W, Jiang SP, Huang L. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci. 2009;13(2):77–80.PubMed
248.
Feldman D, Hochberg MC, Zizic TM, Stevens MB. Cutaneous vasculitis in adult polymyositis/dermatomyositis. J Rheumatol. 1983;10(1):85–9.PubMed
249.
Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. A study of 32 cases. Arch Dermatol. 1990;126(5):633–7.CrossRefPubMed
250.
Burnouf M, Mahe E, Verpillat P, Descamps V, Lebrun-Vignes B, Picard-Dahan C, et al. Cutaneous necrosis is predictive of cancer in adult dermatomyositis. Ann Dermatol Venereol. 2003;130(3):313–6.PubMed
251.
Ponyi A, Constantin T, Garami M, Andras C, Tallai B, Vancsa A, et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci. 2005;1051:64–71.CrossRefPubMed
252.
Gallais V, Crickx B, Belaich S. Cutaneous necrotic lesions in dermatomyositis in adults: a predictive sign of cancer? Presse Med. 1995;24(39):1907.PubMed
253.
Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O’Callaghan A, Martinez-Gomez X, Bosch X, Labrador-Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32.CrossRefPubMed
254.
Trallero-Araguas E, Labrador-Horrillo M, Selva-O’Callaghan A, Martinez MA, Martinez-Gomez X, Palou E, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore). 2010;89(1):47–52.CrossRef
255.
Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147(4):391–8.CrossRefPubMed
256.
Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49(9):1726–33.CrossRef
257.
Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71(5):710–3.CrossRefPubMed
258.
Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360–74.
259.
Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat-Chalumeau N, Frances C, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomark Prev. 2005;14(5):1279–82.CrossRef
260.
Andras C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P, et al. Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol. 2008;35(3):438–44.PubMed
261.
Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathic dermatomyositis. Br J Dermatol. 2007;157(4):637–44.CrossRefPubMed
262.
Morganroth PA, Kreider ME, Okawa J, Taylor L, Werth VP. Interstitial lung disease in classic and skin-predominant dermatomyositis: a retrospective study with screening recommendations. Arch Dermatol. 2010;146(7):729–38.CrossRefPubMed
263.
Ideura G, Hanaoka M, Koizumi T, Fujimoto K, Shimojima Y, Ishii W, et al. Interstitial lung disease associated with amyopathic dermatomyositis: review of 18 cases. Respir Med. 2007;101(7):1406–11.CrossRefPubMed
264.
Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum. 2008;59(5):677–85.CrossRefPubMed
265.
Fathi M, Dastmalchi M, Rasmussen E, Lundberg IE, Tornling G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63(3):297–301.CrossRefPubMed
266.
Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275–85.CrossRefPubMed
267.
Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64(11):3736–40.CrossRefPubMed
268.
Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). 2010;49(9):1713–9.CrossRef
269.
Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.CrossRefPubMed
270.
Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278–84.CrossRef
271.
Chaisson NF, Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore). 2012;91(4):220–8.CrossRef
272.
Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.CrossRefPubMed
273.
Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol. 2012. doi:10.​1002/​ppul.​22742.
Metadata
Title
Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations
Authors
Alisa N. Femia
Ruth Ann Vleugels
Jeffrey P. Callen
Publication date
01-08-2013
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2013
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-013-0028-6

Other articles of this Issue 4/2013

American Journal of Clinical Dermatology 4/2013 Go to the issue

Review Article

Etiology, Diagnosis, and Therapeutic Management of Granuloma Annulare: An Update

Review Article

Immunotherapy for the Management of Advanced Melanoma: The Next Steps

Original Research Article

Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic

Leading Article

Intralesional Antigen Immunotherapy for the Treatment of Warts: Current Concepts and Future Prospects

Review Article

Pharmacotherapeutic Management of Actinic Keratosis: Focus on Newer Topical Agents

Original Research Article

Psychiatric Comorbidities and Alexithymia in Patients with Seborrheic Dermatitis: A Questionnaire Study in Turkey